Q BioMed (Q BioMed) Debt-to-Equity : -0.63 (As of Feb. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Q BioMed Debt-to-Equity?

Q BioMed's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2023 was $4.08 Mil. Q BioMed's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2023 was $0.00 Mil. Q BioMed's Total Stockholders Equity for the quarter that ended in Feb. 2023 was $-6.44 Mil. Q BioMed's debt to equity for the quarter that ended in Feb. 2023 was -0.63.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Q BioMed's Debt-to-Equity or its related term are showing as below:

QBIO's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Q BioMed Debt-to-Equity Historical Data

The historical data trend for Q BioMed's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q BioMed Debt-to-Equity Chart

Q BioMed Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Debt-to-Equity

Get a 7-Day Free Trial

-27.10

-0.73

-0.09

-0.65

-0.89

Q BioMed Quarterly Data
	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23
Debt-to-Equity	Get a 7-Day Free Trial															-0.57	-0.48	-0.52	-0.89	-0.63

Competitive Comparison of Q BioMed's Debt-to-Equity

For the Biotechnology subindustry, Q BioMed's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q BioMed's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q BioMed's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Q BioMed's Debt-to-Equity falls into.

Q BioMed Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Q BioMed's Debt to Equity Ratio for the fiscal year that ended in Nov. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.11	+	0)	/	-4.617
	=	-0.89

Q BioMed's Debt to Equity Ratio for the quarter that ended in Feb. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.083	+	0)	/	-6.441
	=	-0.63

Q BioMed (OTCPK:QBIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Q BioMed Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Q BioMed's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Q BioMed (Q BioMed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q BioMed Inc (OTCPK:QBIO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

C/o Ortoli Rosenstadt LLP, 366 Madison Avenue, 3rd Floor, New York, NY, USA, 10017

Website

https://www.qbiomed.com

Q BioMed Inc is a biomedical acceleration and development company. It has a focus on licensing, acquiring, and providing strategic resources to life sciences and healthcare companies. The company intends to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare-related products, companies, and sectors. Generic Strontium Chloride Sr-89 Injection USP (Strontium-89) is a radioactive pharmaceutical injection to relieve bone pain in patients with painful skeletal metastases. It also has three development-stage products: QBM-001 for rare pediatric non-verbal autism spectrum disorder, Uttroside-B for liver cancer, and MAN 01 for glaucoma.

Executives

William S Rosenstadt	director, 10 percent owner, officer: Chief Legal Officer	ORTOLI ROSENSTADT LLP, 501 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Denis Corin	director, 10 percent owner, officer: Chief Executive Officer	10 MARKET STREET, SUITE 427, GRAND CAYMAN E9 KY1-9006
Rick Panicucci	director	501 MADISON STREET, 14TH FLOOR, NEW YORK NY 10022
Alan P Lindsay	10 percent owner	580 HORNBY STREET, FIFTH FLOOR, VANCOUVER BC CANADA V6C 2E7 A1